Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | PRKCG | P05129 | 1/20 | 0.49 |
| ▸ | PRKCB | P05771 | 1/20 | 0.49 |
| ▸ | IL1R1 | P14778 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.49 |
| ▸ | PRKCH | P24723 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.49 |
| ▸ | TRPC3 | Q13507 | 3/20 | 0.45 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24565448 | 0.88 | PRKD3 (0.46) | HTR2CPRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL24565746 | 0.84 | PRKD3 (0.47) | HTR2CPRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL24565737 | 0.82 | HTR2C (0.44) | HTR2CPRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL24565742 | 0.79 | PRKD3 (0.46) | HTR2CPRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL24565761 | 0.79 | KMT2A (0.43) | HTR2CPRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL22494797 | 0.78 | HTR2C (0.67) | HTR2CTLR7TRPC3TRPC6NPC1 | |
| SCHEMBL22644745 | 0.76 | PRKD3 (0.43) | HTR2CPRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL22637331 | 0.76 | HTR2C (0.46) | HTR2CPRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL24565484 | 0.74 | PRKD3 (0.41) | HTR2CPRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL3537433 | 0.72 | PRKD3 (0.49) | HTR2CPRKD3PRKCGPRKCBIL1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | claimed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | claimed |
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220204495-A1 | INHIBITING TRABID | Valo Health, LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | HTR2C 4293/4885PRKD3 1208/4885PRKCG 1058/4885 |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | USP30, UCHL1, UCHL3 | HTR2C 4172/4885PRKD3 1541/4885PRKCG 2076/4885 |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | HTR2C 4293/4885PRKD3 1208/4885PRKCG 1058/4885 |
| US-20220204495-A1 | INHIBITING TRABID | TPO, PRKACG, NFKBIA | HTR2C 4278/4885PRKD3 114/4885PRKCG 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.